NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

NAUnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

June 30, 2024

Conditions
Drug Resistant Epilepsy
Interventions
DEVICE

NaviFUS System

FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.

Trial Locations (1)

11217

RECRUITING

Taipei Veterans General Hospital, Taipei

Sponsors
All Listed Sponsors
lead

NaviFUS Corporation

INDUSTRY

NCT04999046 - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy | Biotech Hunter | Biotech Hunter